Immunotherapy combinations transform the treatment paradigm for advanced renal cell carcinoma

Justin A. Shaya, Rana R. McKay


Over the past 15 years, the treatment options for patients with advanced renal cell carcinoma (RCC) have undergone tremendous transformation. From single agent vascular endothelial growth factor (VEGF) targeted therapy, to now immunotherapy combinations, survival is improving given the results of landmark clinical trials which have expanded treatments for patients.